Business Wire

Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market

Jaa

Biogen (Nasdaq:BIIB) and Samsung Bioepis Co., Ltd. today announced the European launch of IMRALDI™ (adalimumab), a biosimilar referencing HUMIRA®. Starting today, IMRALDI™ will begin launching in major markets across Europe.

The launch of IMRALDI™ marks a significant milestone for Biogen and Samsung Bioepis, as the adalimumab product is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialized by Biogen across Europe. BENEPALI™ (etanercept) and FLIXABI™ (infliximab) were approved in 2016, and have approximately 100,000 patients currently under treatment with more than 6 million doses administered across 25 and 14 countries, respectively.ii

“We look forward to increasing patient access to this important medicine by leveraging our industry-leading position in the European anti-TNF market,” said Ian Henshaw, Head of Biogen’s Biosimilars Unit.

“The launch of IMRALDI marks what we believe to be a landmark moment for Biogen and Samsung Bioepis and for European healthcare systems. We hope IMRALDI will play an important role widening choice and increasing competition in one of the most high-value areas of the biopharmaceuticals market,” said Sang-Jin Pak, Chief Operating Officer, Samsung Bioepis. “In just six years, Samsung Bioepis has successfully developed the industry’s leading portfolio of anti-TNF biosimilars with a strong pipeline of further biosimilar candidates currently under development.”

“We are proud of our collaboration with Biogen, which brings together the development expertise of Samsung Bioepis with the commercial excellence of Biogen for the benefit of patients across Europe.”

The European Commission (EC) approved IMRALDI™ in August 2017 for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis and uveitis.iii

The EC approval was based on data derived from a randomized, double-blind 52-week Phase 3 study, in which 544 patients with moderate to severe rheumatoid arthritis despite methotrexate (MTX) therapy were randomized to receive either SB5 or the adalimumab reference product (ADL). At Week 24, the ACR20 response rate was 72.4% in the SB5 group versus 72.2% in the ADL group. The safety profile of SB5 was comparable to ADL up to Week 24. At Week 24, 254 patients receiving ADL were re-randomized in a 1:1 ratio to continue on ADL or transitioned to SB5, and 254 patients receiving SB5 continued to receive SB5. Up to Week 52, the efficacy, safety and immunogenicity profiles remained comparable between all three treatment groups. There were no treatment emergent issues or clinically relevant immunogenicity precipitated by alternating subjects between treatments.iv v


About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – TwitterLinkedInFacebookYouTube.

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology and ophthalmology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

Biogen Safe Harbor
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about the potential benefits, safety and efficacy of IMRALDI; the results of certain Phase 3 studies of IMRALDI; the potential of Biogen’s commercial business, including IMRALDI, BENEPALI and FLIXABI; risks and uncertainties associated with drug development and commercialization, including the commercialization of IMRALDI; and market acceptance of biosimilars and related healthcare system matters. These statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including uncertainty of success in commercialization of IMRALDI, which may be impacted by, among other things, the level of preparedness of healthcare providers to treat patients, difficulties in obtaining or changes in the availability of reimbursement for IMRALDI, the effectiveness of sales and marketing efforts and problems with the manufacturing process for IMRALDI; risks related to our dependence on third parties for the development and commercialization of biosimilars; risks of legal actions, regulatory scrutiny or other challenges to biosimilars, including IMRALDI; the occurrence of adverse safety events; failure to obtain regulatory approvals in other jurisdictions; failure to protect intellectual property and other proprietary rights; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen’s expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission. These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this press release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise.

# # #

i Humira® is a registered trademark of AbbVie Biotechnology Ltd.
ii Biogen data on file – ex-factory sales
iii https://www.ema.europa.eu/medicines/human/EPAR/imraldi
iv Weinblatt M, et al. FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study. Annals of the Rheumatic Diseases 2016;75:487.
v Weinblatt M, et al. A Phase III, Randomized, Double-Blind Clinical Study, Comparing SB5, An Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week results) [abstract]. Arthritis Rheumatol 2015;67 (suppl 10).

Contact information

BIOGEN MEDIA CONTACT:
David Caouette
+1 617 679 4945
david.caouette@biogen.com
or
SAMSUNG BIOEPIS MEDIA CONTACT:
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Manifesto: Call for a Successful Transition to Renewables in the Transportation Sector21.11.2018 16:04Tiedote

Political course corrections, coupled with the alarming reports on climate conservation, have led the organizers behind Power2Drive and other endorsers to initiate a manifesto. The aim is to deepen the close connection between e-mobility and renewable sources of energy and achieve a sustainable future. The smarter E Europe, the largest energy industry platform in Europe, will demonstrate the potential held by this combination of mobility and clean energy, and the pressing need to pay greater attention to sector coupling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181121005307/en/ Survey shows: Solar power for refuelling is popular (© Solar Promotion GmbH & Bundesverband Solarwirtschaft e.V. BSW) The organizers behind Power2Drive have formed a strong alliance committed to the idea of a successful transition to renewable sources of energy in the transportation sector. Some of the declaration’s first signatories include the

Knopp Biosciences to Present at the Piper Jaffray 30th Annual Healthcare Conference21.11.2018 14:00Tiedote

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 30th Annual Healthcare Conference to be held in New York, NY on November 27-29. Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, November 27th at 12:50 p.m. Eastern Time. ABOUT KNOPP BIOSCIENCES LLC Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, ti

REPLY: Syskoplan Reply Awarded with the SAP Quality Award in the Innovation Category21.11.2018 12:00Tiedote

Syskoplan Reply, the SAP technology specialist within the Reply Group, has been awarded with the SAP Quality Award from SAP in the Innovation category for a project for the SEA Group. The award honors the latest SAP solutions and it is presented annually at the SAP NOW event. Syskoplan Reply receives the renowned award for the fifth time in a row. The gold award winning project is an innovative SAP Hybris Marketing solution for SEA from Syskoplan Reply. The SEA Group manages both Milan Linate and Milan Malpensa airports and provides all services and related activities. The project consists of implementing SAP Hybris Marketing to design, create and monitor marketing initiatives. The aim is to increase the customer experience of passengers at Milan Malpensa Airport and make their stay a special experience. The cross-departmental, effective marketing campaign is based on the concept of gamification: in the multi-channel campaign, passengers can participate in a treasure hunt "Hashtag Hunt

GSMA Launches New Industry-Wide Initiative to Support Development of Operator Edge Cloud AR/VR21.11.2018 12:00Tiedote

The GSMA today announced the launch of a new industry-wide initiative called The GSMA Cloud AR/VR Forum that will focus on the development of cloud virtual reality (VR) and augmented reality (AR) technology. The programme which was unveiled at Huawei’s 9th Global Mobile Broadband Forum in London, is backed by mobile operators including China Mobile, China Telecom, China Unicom, Deutsche Telekom, KDDI, KT Corp., NTT DOCOMO, SK Telecom, Telefónica, Telenor, TIM, Turkcell and Vodafone, as well as other industry partners including Huawei and HTC. The programme aims to encourage all parties to collaborate on accelerating the delivery and deployment of 5G cloud-based AR/VR services. “Both VR and AR are disruptive forms of immersive multimedia that, combined with operator edge cloud and 5G connectivity, will transform the cost structures of the enterprise and entertainment fields,” commented Alex Sinclair, Chief Technology Officer, GSMA. “Mobile operators will play a key role in its developme

Clientron to exhibit its embedded computing innovations at SPS IPC Drives 201821.11.2018 12:00Tiedote

Clientron Corp., a world-leading supplier of embedded systems, will introduce its intelligent embedded solutions including single board computers, embedded box PC, and industrial panel PC at SPS IPC Drives 2018, taking place at the Exhibition Centre Nuremberg (No.8-512, Hall 8) from 27 to 29 November in Nuremberg, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181121005002/en/ Clientron to exhibit its brand new intelligent embedded systems at SPS IPC Drives 2018 (Photo: Business Wire) The SPS IPC Drives is the leading trade fair for electronic automation solutions. At the show, Clientron will proud to illustrate its embedded computing solutions for factory automation and food industry applications. The advantages of Clientron’s products are designed for high quality, durability, flexibility and maximum compatibility to facilitate the business transformation towards Industry 4.0. During the show, Clientron will intro

Wireless charging makes a world’s first debut on South Western Railway trains in the UK.21.11.2018 12:00Tiedote

Baker Bellfield, one of the UK’s leading suppliers of commercial interior solutions for the rail sector, and Aircharge, global leader in wireless charging solutions for contract use, have announced today the launch of the world’s first fully rail compliant inductive phone wireless charging system. On-train wireless charging will debut on South Western Railway’s (SWR) refurbished and reconfigured class 444 Siemens Desiro five-car EMUs on the London Waterloo – Southampton – Bournmouth – Weymouth route from November 2018. When the refurbishment programme is completed, all 172 of SWR Desiro class trains will have this new feature. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181121005180/en/ The Aircharge - Baker Bellfield mobile phone wireless charging solution for trains (Photo: Business Wire) With mobile devices becoming the best travel companions for personal and business purposes, including the use of mobile check-in appl

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme